MX2010006896A - Ingrediente farmaceutico activo en un soporte solido, amorfo y con una solubilidad mejorada. - Google Patents

Ingrediente farmaceutico activo en un soporte solido, amorfo y con una solubilidad mejorada.

Info

Publication number
MX2010006896A
MX2010006896A MX2010006896A MX2010006896A MX2010006896A MX 2010006896 A MX2010006896 A MX 2010006896A MX 2010006896 A MX2010006896 A MX 2010006896A MX 2010006896 A MX2010006896 A MX 2010006896A MX 2010006896 A MX2010006896 A MX 2010006896A
Authority
MX
Mexico
Prior art keywords
api
solid support
active pharmaceutical
pharmaceutical ingredient
combination preparation
Prior art date
Application number
MX2010006896A
Other languages
English (en)
Inventor
Rok Grahek
Andrej Bastarda
Aleksander Resman
Martin Crnugelj
Original Assignee
Lek Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceuticals filed Critical Lek Pharmaceuticals
Publication of MX2010006896A publication Critical patent/MX2010006896A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención describe una preparación de combinación comprendiendo un ingrediente farmacéutico activo (API) y un soporte sólido farmacéuticamente aceptable, en donde dicho soporte sólido está en una forma particulada insoluble en agua y comprende un material seleccionado de ácido silícico, hidróxido de aluminio e hidróxido de titanio, en donde dicho API es un compuesto teniendo ambos, al menos una porción estructural hidrofóbica que provoca el que API tenga una baja solubilidad en agua o en una solución acuosa, y múltiples grupos hidrofílicos arreglados para formar interacciones intermoleculares múltiples a dicho soporte sólido que involucran unión polar o iónica o de hidrógeno, en donde los grupos hidrofílicos del API son independientemente iguales o diferentes y comprende al menos uno de los grupos consistiendo de grupos OH y halógeno; en donde dicho API es unido a dicho soporte sólido mediante adsorción, y en donde una mayor proporción de dicho PAl está en el estado amorfo. La presente invención también describe una preparación farmacéutica que comprende tal preparación de combinación así como un método para producir tal preparación de combinación.
MX2010006896A 2007-12-21 2008-12-18 Ingrediente farmaceutico activo en un soporte solido, amorfo y con una solubilidad mejorada. MX2010006896A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07150359A EP2072042A1 (en) 2007-12-21 2007-12-21 Active pharmaceutical ingredient on solid support, amorphous and with improved solubility
PCT/EP2008/067875 WO2009080698A1 (en) 2007-12-21 2008-12-18 Active pharmaceutical ingredient on a solid support, amorphous and with an improved solubility

Publications (1)

Publication Number Publication Date
MX2010006896A true MX2010006896A (es) 2010-10-05

Family

ID=39400469

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010006896A MX2010006896A (es) 2007-12-21 2008-12-18 Ingrediente farmaceutico activo en un soporte solido, amorfo y con una solubilidad mejorada.

Country Status (10)

Country Link
US (1) US20100305087A1 (es)
EP (2) EP2072042A1 (es)
JP (1) JP2011506561A (es)
CN (1) CN101903015A (es)
AU (1) AU2008340057A1 (es)
BR (1) BRPI0821565A2 (es)
CA (1) CA2710125A1 (es)
EA (1) EA201070780A1 (es)
MX (1) MX2010006896A (es)
WO (1) WO2009080698A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2238979A1 (en) * 2009-04-06 2010-10-13 LEK Pharmaceuticals d.d. Active pharmaceutical ingredient adsorbed on solid support
CN102764264A (zh) * 2012-07-25 2012-11-07 杭州和泽医药科技有限公司 一种具高溶出度的塞来昔布固体组合物、制备方法及应用
EP2950923B1 (en) * 2013-02-01 2022-03-09 W.R. Grace & CO. - CONN. Porous silica gel as a carrier for liquid technologies
EP3174527B1 (en) * 2014-08-01 2021-02-17 Johnson & Johnson Consumer Inc. Dosage form of sodium ibuprofen dihydrate on mesoporous silica
CN104771761A (zh) * 2015-03-19 2015-07-15 深圳国源国药有限公司 一种创新药用辅料硅化微晶纤维素及其制备方法
DE102016218604A1 (de) 2016-09-27 2018-03-29 Constantin Adams Partikuläres Stoffgemisch, vorzugsweise zur Verwendung bei der Prophylaxe und/oder Behandlung einer Atemwegsstörung

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0129893B1 (en) 1983-06-28 1991-09-04 Takeda Chemical Industries, Ltd. Ground mixture
AU6378796A (en) * 1995-06-06 1996-12-24 Warner-Lambert Company Ranitidine salts on magnesium trisilicate as an adsorbate
KR100759635B1 (ko) * 2001-06-22 2007-09-17 화이자 프로덕츠 인코포레이티드 비정질 약물의 흡착체의 약학 조성물
WO2005011635A2 (en) * 2003-08-04 2005-02-10 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
AU2004308419B2 (en) * 2003-12-24 2011-06-02 Victory Pharma, Inc. Enhanced absorption of modified release dosage forms
EP1905424A3 (en) * 2006-02-02 2008-04-30 Ranbaxy Laboratories Limited Process for the preparation of a pharmaceutical composition comprising stabilized statin particles
EP1849459A1 (en) * 2006-03-06 2007-10-31 Teva Pharmaceutical Industries Ltd. Ezetimibe compositions

Also Published As

Publication number Publication date
US20100305087A1 (en) 2010-12-02
CN101903015A (zh) 2010-12-01
BRPI0821565A2 (pt) 2015-06-16
JP2011506561A (ja) 2011-03-03
EA201070780A1 (ru) 2010-12-30
AU2008340057A1 (en) 2009-07-02
CA2710125A1 (en) 2009-07-02
EP2234602A1 (en) 2010-10-06
EP2072042A1 (en) 2009-06-24
WO2009080698A1 (en) 2009-07-02

Similar Documents

Publication Publication Date Title
MX2010006896A (es) Ingrediente farmaceutico activo en un soporte solido, amorfo y con una solubilidad mejorada.
WO2009078965A8 (en) An improved process to prepare treprostinil, the active ingredient in remodulin®
WO2011067791A3 (en) Process for preparing pharmaceutical ophthalmic compositions
EP3626253A3 (en) Stable formulations of linaclotide
CA2535364A1 (en) Hyaluronic acid nanoparticles
AU2016219654A1 (en) Crystallization method and bioavailability
WO2010057036A3 (en) Solid composition for controlled release of ionizable active agents with poor aqueous solubility at low ph and methods of use thereof
WO2007033316A3 (en) Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces
TW200716202A (en) Pediatric formulation of topiramate
MX2011008344A (es) Composiciones de dosis orales de liberacion retardada que contiene bardoloxona-metilo (cddo-me) amorfo.
EP4293009A3 (en) Fenfluramine compositions and methods of preparing the same
EP3381445A3 (en) Aqueous formulation of antibody stablised by antioxidants for parenteral administration
PL2046292T3 (pl) Preparaty eterów benzymidazolilo-pirydylowych
WO2007010584A3 (en) Controlled-delivery system of pharmacologically active substances, preparation process and medical use thereof
WO2009064681A3 (en) Liquid compositions comprising valsartan
WO2011069037A3 (en) Stabilization and storage of biological pharmaceutical compositions
SI2018153T1 (sl) Tekoči oralni sestavki
IL192190A0 (en) Process for the preparation of pharmaceutical salts of 3-o-(3',3'-dimethylsuccinyl) betulinic acid
WO2011047837A3 (de) Schmelzgranuliertes cinacalcet
EP2746254A3 (en) Oxadiazole derivative active on sphingosine-1-phosphate (s1p)
WO2008114859A1 (ja) ピラゾール誘導体を含有する医薬組成物
IL186058A0 (en) Polymorphs of 3-0-(3',3' -dimethylsuccinyl) betulinic acid di-n-methyl-d-glucamine salt
WO2011130317A3 (en) Therapeutic agents having reduced toxicity
WO2009084041A3 (en) Pharmaceutical compositions of dexibuprofen
WO2010061220A3 (en) Novel processes and pure polymorphs

Legal Events

Date Code Title Description
FA Abandonment or withdrawal